3D printed tumors from patient material
CompanyCarcinotech Ltd., Edinburgh, United Kingdom
The Carcino3D™ technology of the company Carcinotech is developed from patient biopsies, whole blood, and immune cells with a heterogeneous population of cells isolated directly from the biopsy and a detailed characterised patient profile with sequencing and mutation data available. These printed patient tumours are available in 96 or 384 well formats with tumour-specific extracellular matrix (ECM) and can also include tumour infiltrating lymphocytes (T cells, B cells, NK cells, etc.) and tumour-associated macrophages. As per request, also vascularised and irradiated tumours for combination therapies can be developed.
Carcino3D™ Technology
info@carcinotech.co.uk
Added on: 01-30-2023
[1] https://www.carcinotech.co.uk/disease-models/[2] https://www.cellink.com/customer-spotlight/bioprinting-patient-specific-tumor-models-for-individualized-drug-testing/
